Ovid Therapeutics Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Ovid Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • Ovid Therapeutics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 49.8 %, a 145% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 49.8 +29.5 +145% Sep 30, 2024
Q2 2024 45.6 +27 +146% Jun 30, 2024
Q1 2024 42 +24.9 +146% Mar 31, 2024
Q4 2023 30.4 +14 +84.9% Dec 31, 2023
Q3 2023 20.4 +6.41 +46% Sep 30, 2023
Q2 2023 18.6 +7.59 +69.2% Jun 30, 2023
Q1 2023 17.1 +8.78 +106% Mar 31, 2023
Q4 2022 16.4 +9.92 +152% Dec 31, 2022
Q3 2022 13.9 +3.47 +33.1% Sep 30, 2022
Q2 2022 11 -5.45 -33.2% Jun 30, 2022
Q1 2022 8.32 -17.2 -67.4% Mar 31, 2022
Q4 2021 6.52 -38.6 -85.5% Dec 31, 2021
Q3 2021 10.5 -19.2 -64.7% Sep 30, 2021
Q2 2021 16.4 -9.19 -35.9% Jun 30, 2021
Q1 2021 25.5 +4.56 +21.8% Mar 31, 2021
Q4 2020 45.1 +25.2 +127% Dec 31, 2020
Q3 2020 29.7 +7.28 +32.5% Sep 30, 2020
Q2 2020 25.6 Jun 30, 2020
Q1 2020 20.9 Mar 31, 2020
Q4 2019 19.9 Dec 31, 2019
Q3 2019 22.4 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.